Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Zhao M, Wu X, Fan Y, Zhang Y, Guo B, Yu J, Cao G, Chen Y, Wu J, Shi Y, Li J, Zhang J. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents 2018;51:714-20. [DOI: 10.1016/j.ijantimicag.2017.12.025] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 12/17/2017] [Accepted: 12/24/2017] [Indexed: 12/13/2022]

For:	Zhao M, Wu X, Fan Y, Zhang Y, Guo B, Yu J, Cao G, Chen Y, Wu J, Shi Y, Li J, Zhang J. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents 2018;51:714-20. [DOI: 10.1016/j.ijantimicag.2017.12.025] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 12/17/2017] [Accepted: 12/24/2017] [Indexed: 12/13/2022]

Number

Cited by Other Article(s)

Qi B, Gijsen M, De Vocht T, Deferm N, Van Brantegem P, Abza GB, Nauwelaerts N, Wauters J, Spriet I, Annaert P. Unravelling the Hepatic Elimination Mechanisms of Colistin. Pharm Res 2023;40:1723-1734. [PMID: 37258948 DOI: 10.1007/s11095-023-03536-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 05/13/2023] [Indexed: 06/02/2023]

Zhu S, Zhang J, Lv Z, Zhu P, Oo C, Yu M, Sy SKB. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet 2022;61:1427-1441. [PMID: 35947360 DOI: 10.1007/s40262-022-01161-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/20/2022] [Indexed: 01/10/2023]

Abstract

BACKGROUND

The combination of polymyxins, meropenem, and sulbactam demonstrated efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three antibiotics are commonly used against major blood, skin, lung, and heart muscle infections.

OBJECTIVE

The objective of this study was to predict drug disposition and extrapolate the efficacy in these tissues using a physiologically based pharmacokinetic modeling approach that linked drug exposures to their target pharmacodynamic indices associated with antimicrobial activities against A. baumannii.

METHODS

An adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances. The model reliability was evaluated by comparing simulated plasma and tissue drug exposures to observed data. Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage.

RESULTS

The modeled plasma drug exposures in adults and pediatric patients were consistent with reported literature data. The mean fold errors for meropenem, colistin, and sulbactam were in the range of 0.710-1.37, 0.981-1.47, and 0.647-1.39, respectively. Simulated exposures in the blood, skin, lung, and heart were consistent with reported penetration rates. In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity.

CONCLUSIONS

The physiologically based pharmacokinetic modeling supports pediatric dosing regimens of meropenem/colistin/sulbactam in a co-administration setting against infections in the blood, lung, skin, and heart tissues due to A. baumannii.

Collapse

Fan Y, Li Y, Chen Y, Yu J, Liu X, Li W, Guo B, Li X, Wang J, Wu H, Wang Y, Hu J, Guo Y, Hu F, Xu X, Cao G, Wu J, Zhang Y, Zhang J, Wu X. Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen. Antibiotics (Basel) 2022;11:antibiotics11060798. [PMID: 35740204 PMCID: PMC9220111 DOI: 10.3390/antibiotics11060798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Revised: 06/01/2022] [Accepted: 06/07/2022] [Indexed: 01/27/2023] Open

Affiliation(s)

Yaxin Fan Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Yi Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Yuancheng Chen Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China
Jicheng Yu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China
Xiaofen Liu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Wanzhen Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Beining Guo Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Xin Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Jingjing Wang Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China
Hailan Wu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Yu Wang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Jiali Hu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Yan Guo Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Fupin Hu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Xiaoyong Xu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Guoying Cao Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China
Jufang Wu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China
Yingyuan Zhang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
Jing Zhang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China; (Y.F.); (Y.L.); (X.L.); (W.L.); (B.G.); (X.L.); (H.W.); (Y.W.); (J.H.); (Y.G.); (F.H.); (X.X.); (Y.Z.) Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China Correspondence: (J.Z.); (X.W.)
Xiaojie Wu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai 200040, China; (Y.C.); (J.Y.); (J.W.); (G.C.); (J.W.) National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China Correspondence: (J.Z.); (X.W.)

Collapse

Population Pharmacokinetics of Colistin Methanesulfonate Sodium and Colistin in Critically Ill Patients: A Systematic Review. Pharmaceuticals (Basel) 2021;14:ph14090903. [PMID: 34577603 PMCID: PMC8472798 DOI: 10.3390/ph14090903] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/01/2021] [Accepted: 09/01/2021] [Indexed: 02/06/2023] Open

Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol Rev 2021;73:679-728. [PMID: 33627412 PMCID: PMC7911091 DOI: 10.1124/pharmrev.120.000020] [Citation(s) in RCA: 160] [Impact Index Per Article: 53.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open

Abstract

Antibiotic resistance is a major global health challenge and, worryingly, several key Gram negative pathogens can become resistant to most currently available antibiotics. Polymyxins have been revived as a last-line therapeutic option for the treatment of infections caused by multidrug-resistant Gram negative bacteria, in particular Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales. Polymyxins were first discovered in the late 1940s but were abandoned soon after their approval in the late 1950s as a result of toxicities (e.g., nephrotoxicity) and the availability of "safer" antibiotics approved at that time. Therefore, knowledge on polymyxins had been scarce until recently, when enormous efforts have been made by several research teams around the world to elucidate the chemical, microbiological, pharmacokinetic/pharmacodynamic, and toxicological properties of polymyxins. One of the major achievements is the development of the first scientifically based dosage regimens for colistin that are crucial to ensure its safe and effective use in patients. Although the guideline has not been developed for polymyxin B, a large clinical trial is currently being conducted to optimize its clinical use. Importantly, several novel, safer polymyxin-like lipopeptides are developed to overcome the nephrotoxicity, poor efficacy against pulmonary infections, and narrow therapeutic windows of the currently used polymyxin B and colistin. This review discusses the latest achievements on polymyxins and highlights the major challenges ahead in optimizing their clinical use and discovering new-generation polymyxins. To save lives from the deadly infections caused by Gram negative "superbugs," every effort must be made to improve the clinical utility of the last-line polymyxins. SIGNIFICANCE STATEMENT: Antimicrobial resistance poses a significant threat to global health. The increasing prevalence of multidrug-resistant (MDR) bacterial infections has been highlighted by leading global health organizations and authorities. Polymyxins are a last-line defense against difficult-to-treat MDR Gram negative pathogens. Unfortunately, the pharmacological information on polymyxins was very limited until recently. This review provides a comprehensive overview on the major achievements and challenges in polymyxin pharmacology and clinical use and how the recent findings have been employed to improve clinical practice worldwide.

Collapse

Affiliation(s)

Sue C Nang Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia (S.C.N., M.A.K.A., J.L.); Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia (T.V.); and Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana (Q.T.Z.)
Mohammad A K Azad Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia (S.C.N., M.A.K.A., J.L.); Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia (T.V.); and Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana (Q.T.Z.)
Tony Velkov Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia (S.C.N., M.A.K.A., J.L.); Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia (T.V.); and Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana (Q.T.Z.)
Qi Tony Zhou Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia (S.C.N., M.A.K.A., J.L.); Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia (T.V.); and Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana (Q.T.Z.)
Jian Li Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, Victoria, Australia (S.C.N., M.A.K.A., J.L.); Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia (T.V.); and Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana (Q.T.Z.)

Collapse

Fan YX, Chen YC, Li Y, Yu JC, Bian XC, Li X, Li WZ, Guo BN, Wu HL, Liu XF, Wang Y, Xu XY, Hu JL, Wang JJ, Wu XJ, Cao GY, Wu JF, Xue CJ, Feng J, Zhang YY, Zhang J. Effects of Different Component Contents of Colistin Methanesulfonate on the Pharmacokinetics of Prodrug and Formed Colistin in Human. Pharm Res 2021;38:79-87. [PMID: 33496870 DOI: 10.1007/s11095-021-02991-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 12/07/2020] [Indexed: 11/30/2022]

Affiliation(s)

Ya-Xin Fan Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Yuan-Cheng Chen Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Yi Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Ji-Cheng Yu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Xing-Chen Bian Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Xin Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Wan-Zhen Li Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Bei-Ning Guo Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Hai-Lan Wu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Xiao-Fen Liu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Yu Wang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Xiao-Yong Xu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Jia-Li Hu Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Jing-Jing Wang Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Xiao-Jie Wu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Guo-Ying Cao Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Ju-Fang Wu Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Phase I Unit, Huashan Hospital, Fudan University, Shanghai, 200040, China
Chun-Jia Xue Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China
Jun Feng Shanghai Institute of Pharmaceutical Industry, Shanghai, 201203, China
Ying-Yuan Zhang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China.,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China.,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China
Jing Zhang Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, China. .,Key Laboratory of Clinical Pharmacology of Antibiotics, National Population and Family Planning Commission, Shanghai, 200040, China. .,National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China.

Collapse

Therapeutic drug monitoring of polymyxin B by LC-MS/MS in plasma and urine. Bioanalysis 2020;12:845-855. [PMID: 32558589 DOI: 10.4155/bio-2020-0051] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open

Zhou YF, Liu P, Zhang CJ, Liao XP, Sun J, Liu YH. Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat Escherichia coli Harboring bla _NDM- ₅ and mcr-1. Front Microbiol 2020;10:2957. [PMID: 31969868 PMCID: PMC6960404 DOI: 10.3389/fmicb.2019.02957] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 12/09/2019] [Indexed: 01/20/2023] Open

Affiliation(s)

Yu-Feng Zhou National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
Ping Liu National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
Chuan-Jian Zhang National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
Xiao-Ping Liao National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
Jian Sun National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China
Ya-Hong Liu National Risk Assessment Laboratory for Antimicrobial Resistance of Animal Original Bacteria, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.,Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, China.,Jiangsu Co-innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonosis, Yangzhou University, Yangzhou, China

Collapse

Wang Y, Li H, Xie X, Wu X, Li X, Zhao Z, Luo S, Wan Z, Liu J, Fu L, Li X. In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli. J Glob Antimicrob Resist 2019;20:351-359. [PMID: 31557565 DOI: 10.1016/j.jgar.2019.09.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Revised: 09/06/2019] [Accepted: 09/16/2019] [Indexed: 10/25/2022] Open

An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection. Antibiotics (Basel) 2019;8:antibiotics8030100. [PMID: 31344885 PMCID: PMC6784070 DOI: 10.3390/antibiotics8030100] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 07/07/2019] [Accepted: 07/08/2019] [Indexed: 12/18/2022] Open

Sorlí L, Luque S, Li J, Campillo N, Danés M, Montero M, Segura C, Grau S, Horcajada JP. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. J Infect 2019;79:253-261. [PMID: 31265867 DOI: 10.1016/j.jinf.2019.06.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Revised: 06/15/2019] [Accepted: 06/20/2019] [Indexed: 12/31/2022]

Abstract

OBJECTIVES

Optimal dosage regimens of colistin for the treatment of urinary tract infections (UTI) are unknown. Colistimethate sodium (CMS), the inactive prodrug of colistin, is mainly excreted in urine and converts to colistin after filtration by glomeruli, suggesting that concentrations of colistin in urine could be much higher than in plasma. Therefore, there is a need to optimize dosage regimens of intravenous CMS for UTI. The aim of this study was to examine the relationship between AUC/MIC of formed colistin and clinical outcomes in patients with UTI caused by extremely drug resistant (XDR) Pseudomonas aeruginosa.

METHODS

This prospective, observational cohort study involved patients with UTI caused by XDR P. aeruginosa. Clinical cure, bacteriological clearance and acute kidney injury (AKI) were analyzed. Steady-state colistin plasma concentrations (C_ss) were measured using HPLC. Based on the PK/PD of colistin in neutropenic mouse thigh infection models with P. aeruginosa, the optimal AUC/MIC should be ≥60 mg·h/L. According to the pharmacokinetics (PK) in critically-ill patients, the C_ss target of formed colistin in plasma was 2.5 mg/L.

RESULTS

Thirty-three patients were included (24 lower UTI and 9 pyelonephritis). The MIC₅₀ and MIC₉₀ values for colistin were 0.5 and 2 mg/L respectively. Nineteen patients (57.6%) received colistin monotherapy (84.2% lower UTI and 15.8% pyelonephritis). Of these, clinical cure was achieved in 89.5% of cases. Among patients with clinical cure and monotherapy, only 5 (29.4%) attained an optimal plasma AUC/MIC and only 1 (5.9%) the therapeutic level of formed colistin (2.5 mg/L). However, 10 (58.8%) patients showed colistin plasma concentrations above the MIC of the isolated P. aeruginosa. Microbiological eradication was achieved in 76.9% of patients. AKI at the end of treatment was present in 29.4% of patients.

CONCLUSIONS

The currently recommended dosage regimens of CMS showed high efficacy for the treatment of lower complicated UTI caused by XDR P. aeruginosa in non-critically ill patients and in the case of low MIC values, but also a considerable nephrotoxicity rate. Our data suggest that the use of lower CMS doses for lower UTI should be investigated in future studies to minimize the unnecessary nephrotoxicity.

Collapse

Affiliation(s)

Luisa Sorlí Infectious Diseases Department, Parc de Salut Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain; Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; CEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, Madrid, Spain.
Sonia Luque Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, Madrid, Spain; Pharmacy Department, Parc de Salut Mar. Passeig Marítim 25-29, E-08003 Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Jian Li Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia
Núria Campillo Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Pharmacy Department, Parc de Salut Mar. Passeig Marítim 25-29, E-08003 Barcelona, Spain
Marc Danés CEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain
Milagro Montero Infectious Diseases Department, Parc de Salut Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain; Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; CEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Concha Segura Laboratori de Referència de Catalunya, Carrer de la Selva, 10, E-08820 Prat de Llobregat (El), Barcelona
Santiago Grau Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, Madrid, Spain; Pharmacy Department, Parc de Salut Mar. Passeig Marítim 25-29, E-08003 Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Juan Pablo Horcajada Infectious Diseases Department, Parc de Salut Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain; Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; CEXS-Universitat Pompeu Fabra (UPF), Barcelona, Spain; Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, Madrid, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Collapse

Azad MAK, Nation RL, Velkov T, Li J. Mechanisms of Polymyxin-Induced Nephrotoxicity. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2019;1145:305-319. [PMID: 31364084 DOI: 10.1007/978-3-030-16373-0_18] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]

Nation RL, Forrest A. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2019;1145:219-249. [PMID: 31364081 DOI: 10.1007/978-3-030-16373-0_15] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]